LivaNova PLC (LIVN)

LivaNova PLC (LIVN) Q4 2025 Earnings Call Transcript

While the top- and bottom-line numbers for LivaNova (LIVN) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

LivaNova (LIVN) came out with quarterly earnings of $0.86 per share, beating the Zacks Consensus Estimate of $0.8 per share. This compares to earnings of $0.81 per share a year ago.

LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported fourth-quarter and full-year 2025 results and issued full-year 2026 guidance. Financial Summary and Highlights(1) Fourth-quarter revenue of $360.9 million increased 12.1% on a reported basis and 9.5% on both a constant-currency and organic basis as compared to the prior-year period Fourth-quarter U.S. GAAP diluted earnings per share of $0.56 and adjusted diluted earnings per share o.

Shares of LivaNova PLC (NASDAQ: LIVN - Get Free Report) have earned a consensus rating of "Moderate Buy" from the nine research firms that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation and six have issued a buy recommendation on

Emerald Advisers LLC raised its stake in LivaNova PLC (NASDAQ: LIVN) by 2.3% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 551,162 shares of the company's stock after purchasing an additional 12,163 shares during the quarter. Emerald Advisers LLC

Campbell and CO Investment Adviser LLC acquired a new position in shares of LivaNova PLC (NASDAQ: LIVN) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 15,227 shares of the company's stock, valued at approximately $798,000. Several other large investors have

LivaNova PLC (LIVN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

LivaNova PLC (NASDAQ: LIVN - Get Free Report) has been assigned an average rating of "Moderate Buy" from the nine research firms that are presently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating on

LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced it will present at the J.P. Morgan 44th Annual Healthcare Conference in San Francisco. Vladimir Makatsaria, Chief Executive Officer of LivaNova, and Alex Shvartsburg, Chief Financial Officer, will participate in a fireside chat on Wed., Jan. 14, 2026, at 1:30 p.m. Pacific Standard Time. The discussion will be available to all interested parties who register to attend the webcast, w.

LivaNova PLC (NASDAQ: LIVN - Get Free Report) has received an average recommendation of "Moderate Buy" from the eight analysts that are covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company. The

Sintx Technologies (NASDAQ: SINT - Get Free Report) and LivaNova (NASDAQ: LIVN - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, valuation, risk, earnings and profitability. Institutional and Insider Ownership 18.4% of Sintx Technologies shares

LONDON--(BUSINESS WIRE)---- $LIVN #epilepsy--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced it will present eight posters at the American Epilepsy Society (AES) Annual Meeting, taking place Dec. 5-9 in Atlanta. These presentations highlight real-world evidence from the CORE-VNS study, the largest prospective, multinational observational study of VNS Therapy™ for Drug-Resistant Epilepsy (DRE), and new health economics analyses. “At the heart of LivaNova's purpose as a Comp.

LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, announced Lucile Blaise has joined the Company as Global Head of Commercialization, Obstructive Sleep Apnea (OSA), effective December 1. Blaise reports to Vladimir Makatsaria, Chief Executive Officer and is a member of the Executive Leadership Team. “Lucile is an accomplished healthcare executive with more than 25 years of leadership in the medtech sector,” Makatsaria said. “With her extensive OSA.

Envestnet Asset Management Inc. trimmed its stake in shares of LivaNova PLC (NASDAQ: LIVN) by 78.4% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 10,118 shares of the company's stock after selling 36,715 shares during the period. Envestnet

LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that Alex Shvartsburg, Chief Financial Officer, will present a general business update during a fireside chat at the Piper Sandler 37th Annual Healthcare Conference in New York City. The presentation will take place on Tues., Dec. 2, at 1:30 p.m. Eastern Standard Time. The discussion will be available to all interested parties who register to attend the webcast, which is accessible.